Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 7
1982 38
1983 76
1984 97
1985 86
1986 104
1987 165
1988 261
1989 352
1990 444
1991 396
1992 273
1993 619
1994 725
1995 939
1996 930
1997 956
1998 1042
1999 1107
2000 1161
2001 1432
2002 1409
2003 1505
2004 1637
2005 1883
2006 2247
2007 2596
2008 2918
2009 3382
2010 3887
2011 4326
2012 4500
2013 4573
2014 4842
2015 5060
2016 5184
2017 5578
2018 5429
2019 3123
2020 120
Text availability
Article attribute
Article type
Publication date

Search Results

67,262 results
Results by year
Filters applied: . Clear all
Page 1
Drug Development of Therapeutic Monoclonal Antibodies.
Mould DR, Meibohm B. Mould DR, et al. BioDrugs. 2016 Aug;30(4):275-93. doi: 10.1007/s40259-016-0181-6. BioDrugs. 2016. PMID: 27342605 Review.
Subcutaneous delivery of monoclonal antibodies: How do we get there?
Viola M, Sequeira J, Seiça R, Veiga F, Serra J, Santos AC, Ribeiro AJ. Viola M, et al. J Control Release. 2018 Sep 28;286:301-314. doi: 10.1016/j.jconrel.2018.08.001. Epub 2018 Aug 2. J Control Release. 2018. PMID: 30077735 Review.
Fixed Dosing of Monoclonal Antibodies in Oncology.
Hendrikx JJMA, Haanen JBAG, Voest EE, Schellens JHM, Huitema ADR, Beijnen JH. Hendrikx JJMA, et al. Oncologist. 2017 Oct;22(10):1212-1221. doi: 10.1634/theoncologist.2017-0167. Epub 2017 Jul 28. Oncologist. 2017. PMID: 28754722 Free PMC article. Review.
A tale of two antibodies: obinutuzumab versus rituximab.
Freeman CL, Sehn LH. Freeman CL, et al. Br J Haematol. 2018 Jul;182(1):29-45. doi: 10.1111/bjh.15232. Epub 2018 May 9. Br J Haematol. 2018. PMID: 29741753 Review.
Immune Checkpoint Inhibitors-Induced Hepatitis.
Tian Y, Abu-Sbeih H, Wang Y. Tian Y, et al. Adv Exp Med Biol. 2018;995:159-164. doi: 10.1007/978-3-030-02505-2_8. Adv Exp Med Biol. 2018. PMID: 30539511 Review.
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, Papp KA, Sofen H, Puig L, Foley P, Ohtsuki M, Flack M, Geng Z, Gu Y, Valdes JM, Thompson EHZ, Bachelez H. Gordon KB, et al. Lancet. 2018 Aug 25;392(10148):650-661. doi: 10.1016/S0140-6736(18)31713-6. Epub 2018 Aug 7. Lancet. 2018. PMID: 30097359 Clinical Trial.
Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.
Tepper S, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein S, Winner P, Leonardi D, Mikol D, Lenz R. Tepper S, et al. Lancet Neurol. 2017 Jun;16(6):425-434. doi: 10.1016/S1474-4422(17)30083-2. Epub 2017 Apr 28. Lancet Neurol. 2017. PMID: 28460892 Clinical Trial.
67,262 results
Jump to page
Feedback